How are you taking part in this consultation?

You will not be able to change how you comment later.

You must be signed in to answer questions

  • Question on Consultation

    Has all of the relevant evidence been taken into account?

  • Question on Consultation

    Are the summaries of clinical and cost effectiveness reasonable interpretations of the evidence?

  • Question on Consultation

    Are the recommendations sound and a suitable basis for guidance to the NHS?

  • Question on Consultation

    Are there any aspects of the recommendations that need particular consideration to ensure we avoid unlawful discrimination against any group of people on the grounds of race, gender, disability, religion or belief, sexual orientation, age, gender reassignment, pregnancy and maternity?
The content on this page is not current guidance and is only for the purposes of the consultation process.

Draft guidance consultation

Closed for comments This consultation ended on at   Request commenting lead permission

2 Information about garadacimab

Marketing authorisation indication

2.1

Garadacimab (Andembry, CSL Behring) is indicated for 'routine prevention of recurrent attacks of hereditary angioedema (HAE) in adult and adolescent patients aged 12 years and older'.

Price

2.3

The list price of garadacimab for subcutaneous injection by pre-filled pen is confidential until published by the Department for Health and Social Care.

2.4

The company has a commercial arrangement, which would have applied if garadacimab had been recommended.

Carbon Reduction Plan

2.5

Information on the Carbon Reduction Plan for UK carbon emissions for CSL Behring will be included here when guidance is published.